Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/30402
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | MARTENS, Pieter | - |
dc.contributor.author | Verluyten, Lina | - |
dc.contributor.author | Van de Broek, Heleen | - |
dc.contributor.author | Somers, Frauke | - |
dc.contributor.author | DAUW, Jeroen | - |
dc.contributor.author | DUPONT, Matthias | - |
dc.contributor.author | MULLENS, Wilfried | - |
dc.date.accessioned | 2020-01-24T11:51:25Z | - |
dc.date.available | 2020-01-24T11:51:25Z | - |
dc.date.issued | 2021 | - |
dc.date.submitted | 2020-01-23T14:13:45Z | - |
dc.identifier.citation | ACTA CARDIOLOGICA, 76 (1), p. 20-29 | - |
dc.identifier.issn | 0001-5385 | - |
dc.identifier.uri | http://hdl.handle.net/1942/30402 | - |
dc.description.abstract | Background: Little information is available about the tolerability of uptitration to the maximal dose of sacubitril/valsartan and the predictors and clinical correlates of achieving such a dose. Methods: All consecutive heart failure patients with reduced ejection fraction (HFrEF) who received sacubitril/valsartan for a class-IB indication in a tertiary heart failure clinic were retrospectively analysed. Predictors of maximal uptitration including associated changes in clinical parameters were assessed in patients with at least 1 follow-up. Results: A total of 401 HFrEF-patients received sacubitril/valsartan. Uptitration was possible in 41% and up to 32% of patients tolerated the maximal dose of sacubitril/valsartan. Younger age (HR = 0.862; CI = 0.751-0.989), higher systolic-blood-pressure (HR = 1.077; CI = 1.014-1.137), lower serum creatinine (HR = 0.064; CI = 0.005-0.822), and higher previous dose of renin-angiotensin-system-inhibitors (RASi [HR = 1.065; CI = 1.016-1.115]) independently predicted a higher odds of tolerating a maximal dose of sacubitril/valsartan. Patients who were seen more frequently in a structured heart failure clinic were also more likely to receive a maximal dose (p = .038). Patient assigned to the maximal dose, were more often able to reduce their loop diuretic dose (p = .001) and more often had an increase in serum creatinine (p = .011), without a higher risk for hyperkalemia (p = .524). An improvement in New York Heart Association class and the rate of heart failure hospitalisations was observed in all patients, independent of the sacubitril/valsartan dose. Conclusion: Uptitration to the maximal dose of sacubitril/valsartan is possible in up to 32% of real-world HFrEF-patients in our cohort, which relates to both patient characteristics' as well as heart failure care-related factors. | - |
dc.description.sponsorship | Pieter Martens is supported by a doctoral fellowship by the Research Foundation-Flanders (FWO, grant-number: 1127917N). Pieter Martens and Wilfried Mullens are researchers for the Limburg Clinical Research Centre (LCRC) UHasselt-ZOL-Jessa, supported by the foundation Limburg Sterk Merk (LSM), Hasselt University, Ziekenhuis OostLimburg, and Jessa Hospital. | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.rights | 2019 Belgian Society of Cardiology | - |
dc.subject.other | Heart failure | - |
dc.subject.other | sacubitril/valsartan | - |
dc.subject.other | dosing | - |
dc.subject.other | outcome | - |
dc.subject.other | guidelines | - |
dc.subject.other | real world evidence | - |
dc.title | Determinants of maximal dose titration of sacubitril/valsartan in clinical practice | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 29 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | 20 | - |
dc.identifier.volume | 76 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | Martens, P (reprint author), Ziekenhuis Oost Limburg, Dept Cardiol, Schiepse Bos 6, B-3600 Genk, Belgium. | - |
dc.description.notes | pieter_martens@icloud.com | - |
dc.description.other | Martens, P (reprint author), Ziekenhuis Oost Limburg, Dept Cardiol, Schiepse Bos 6, B-3600 Genk, Belgium pieter_martens@icloud.com | - |
local.publisher.place | 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.source.type | Article | - |
dc.identifier.doi | 10.1080/00015385.2019.1686226 | - |
dc.identifier.pmid | 31697901 | - |
dc.identifier.isi | WOS:000495010000001 | - |
dc.identifier.eissn | 1784-973X | - |
local.provider.type | wosris | - |
local.uhasselt.uhpub | yes | - |
local.uhasselt.international | no | - |
item.validation | ecoom 2020 | - |
item.accessRights | Restricted Access | - |
item.fullcitation | MARTENS, Pieter; Verluyten, Lina; Van de Broek, Heleen; Somers, Frauke; DAUW, Jeroen; DUPONT, Matthias & MULLENS, Wilfried (2021) Determinants of maximal dose titration of sacubitril/valsartan in clinical practice. In: ACTA CARDIOLOGICA, 76 (1), p. 20-29. | - |
item.fulltext | With Fulltext | - |
item.contributor | MARTENS, Pieter | - |
item.contributor | Verluyten, Lina | - |
item.contributor | Van de Broek, Heleen | - |
item.contributor | Somers, Frauke | - |
item.contributor | DAUW, Jeroen | - |
item.contributor | DUPONT, Matthias | - |
item.contributor | MULLENS, Wilfried | - |
crisitem.journal.issn | 0001-5385 | - |
crisitem.journal.eissn | 1784-973X | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
pieter martens 2019.pdf Restricted Access | Published version | 1.42 MB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
2
checked on Sep 5, 2020
WEB OF SCIENCETM
Citations
10
checked on May 8, 2024
Page view(s)
46
checked on Jul 22, 2022
Download(s)
4
checked on Jul 22, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.